Nova Eye Medical (ELXMF)
OTHER OTC:ELXMF
ELXMF Stock Chart & Stats
$0.25
$0.00(0.00%)
At close: 4:00 PM EDT
$0.25
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.10 - $0.25
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$25.16M
Enterprise Value$39.35M
Total Cash (Recent Filing)$2.62M
Total Debt (Recent Filing)$4.94M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding284,840,270
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit1.78
Enterprise Value/Ebitda-10.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$24.12M
Bulls Say, Bears Say
Bulls Say
Niche Product Focus & ConsumablesA focused product set on ophthalmic surgical devices plus consumables supports recurring revenue and deep clinical relationships. Consumables can produce annuity-like sales to clinics and surgeons, raising lifetime customer value and providing durable revenue visibility as procedures continue.
Consistent Top-line GrowthMid-teens revenue growth indicates sustained market demand and adoption of the company's products. Over a 2–6 month horizon, consistent revenue expansion supports operating scale, helps absorb fixed costs, and underpins reinvestment in R&D and commercialization to entrench market position.
Low Financial LeverageA low debt-to-equity ratio preserves financial flexibility to fund R&D, scale manufacturing, or pursue partnerships without heavy interest burden. This balance sheet strength reduces refinancing risk and supports multi-quarter investments needed in medical device commercialization.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows constrain the company’s ability to self-fund growth and sustain commercial expansion. Over months this forces reliance on external financing or equity dilution, limiting strategic optionality and increasing execution risk for product rollouts and market expansion.
Material Gross Margin DeteriorationA sharp drop in gross margin signals rising production costs or pricing pressure, which erodes the core economics of the business. Unless margins are stabilized by pricing, cost control, or product mix improvement, margin compression will persistently reduce free cash flow and capacity to invest.
Ongoing Unprofitability And Negative ROENegative net profit and a negative return on equity indicate the company is not converting sales into shareholder returns. Over a medium horizon, sustained losses impair retained earnings, limit reinvestment without dilution, and challenge credibility with customers and partners if investment in commercialization falters.
Nova Eye Medical News
ELXMF FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest stock price was $0.10 and its highest was $0.25 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is $25.16M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 27, 2026 which is in 141 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -$0.008 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.005.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Notavailable dividend of $0.294 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,840,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -$0.008 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in ELXMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELXMF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $7.7K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-44.16%
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---